A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (ACTRN12624001468516)
Daratumumab@Home
This trial is Currently recruiting
Registration number ACTRN12624001468516
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 2
Trial participation type
This trial is for clinical research of something other than a drug or device.
Principal investigator
Dr Shafqat Inam
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.